Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Background Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and d...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
BMJ Publishing Group
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/ea3dbbcfc7aa40dd9cf2d630e1cec0b6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|